Clinical Trials Browser

Interventional × dostarlimab × 30 days × Clear all

Rectal Neoplasms

NCT06256588 2026-05-26

JADE

Phase 3 Recruiting

864 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05277051 2026-05-22

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

152 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06062420 2026-05-22

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Phase 2 Active not recruiting

316 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06551142 2026-05-22

PanTumor-101

Phase 1 Recruiting

845 enrolled

Tumor-Agnostic

Neoplasms

NCT06567782 2026-05-22

AZUR-4

Phase 2 Recruiting

120 enrolled

Gastrointestinal

Colonic Neoplasms

NCT06796907 2026-05-22

BEHOLD-2

Phase 1/2 Recruiting

305 enrolled

Tumor-Agnostic

Neoplasms

NCT05819892 2026-05-20

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Phase 1 Recruiting

21 enrolled

Gynecologic

Endometrial Neoplasms

NCT04165772 2026-05-13

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Phase 2 Recruiting

212 enrolled

Gastrointestinal

Rectal Neoplasms

NCT04584255 2026-05-13

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Phase 2 Active not recruiting

62 enrolled

Breast

Breast Neoplasms

NCT04774419 2026-05-13

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

Phase 2 Recruiting

62 enrolled

Gynecologic

Endometrial Neoplasms

NCT04313504 2026-05-07

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

Phase 2 Completed

10 enrolled 9 charts

Head & Neck

Head and Neck Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04126200 2026-05-06

DREAMM 5

Phase 1/2 Active not recruiting

208 enrolled 5 charts

Plasma cell

Multiple Myeloma

NCT06023862 2026-05-06

DOVE

Phase 2 Recruiting

198 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

Clinical Trials

AZUR-1

JADE

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

PanTumor-101

AZUR-4

BEHOLD-2

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

I-SPY

DREAMM 5

DOVE